Is bigger better for depression trials?

Area of Science:

• Clinical Psychology
• Psychopharmacology
• Biostatistics

Background:

• Clinical trial power typically increases with sample size, assuming a fixed effect size.
• This assumption may be invalid in therapeutic areas with heterogeneous patient populations.
• Late-enrolling patients might originate from a more diverse group, impacting study power.

Purpose of the Study:

• To evaluate the impact of patient enrollment heterogeneity on study power in depression trials.
• To analyze post hoc data from four phase III clinical trials of paroxetine for depression.

Main Methods:

• Utilized data from four randomized, double-blind, placebo-controlled phase III depression trials.
• Enrolled approximately 150 patients per treatment arm in each study.
• Generated plots of p-values for treatment differences (paroxetine vs. placebo) against cumulative enrollment.

Main Results:

• Three of four studies showed significant treatment effects overall.
• Significant treatment effects were observed before enrolling 100 patients per arm.
• Further enrollment did not consistently maintain significance; one study's outcome worsened.
• Late-enrolling patients showed higher placebo response rates, suggesting population changes.
• No definitive evidence supported hypotheses of a depleted patient pool or recruitment rush.

Conclusions:

• Larger sample sizes are not inherently superior for depression clinical trials.
• Patient population characteristics may change during enrollment, affecting study outcomes.
• The assumption of a fixed effect size over time warrants careful consideration in trial design.